{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:41:20Z","timestamp":1782942080736,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07418-x","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:27:36Z","timestamp":1766500056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cancer vaccine overcomes immune evasion of nasopharyngeal carcinoma by restoring MHC-I through transcriptional regulation of NLRC5"],"prefix":"10.1186","volume":"23","author":[{"given":"Chai Phei","family":"Gan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sau Yee","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard Kok Bang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Zulaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sok Ching","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Savelyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5670-8070","authenticated-orcid":false,"given":"Kue Peng","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"7418_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.14639\/0392-100X-N2222","volume":"43","author":"G Cant\u00f9","year":"2023","unstructured":"Cant\u00f9 G. Nasopharyngeal carcinoma. A \u201cdifferent\u201d head and neck tumour. Part a: from histology to staging. Acta Otorhinolaryngol Ital. 2023;43:85\u201398.","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"7418_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.radonc.2014.02.003","volume":"110","author":"AWM Lee","year":"2014","unstructured":"Lee AWM, Ng WT, Chan LLK, Hung WM, Chan CCC, Sze HCK, et al. Evolution of treatment for nasopharyngeal cancer \u2013 success and setback in the intensity-modulated radiotherapy era. Radiother Oncol. 2014;110:377\u201384.","journal-title":"Radiother Oncol"},{"key":"7418_CR3","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2147\/OTT.S188148","volume":"12","author":"F Perri","year":"2019","unstructured":"Perri F, Della Vittoria Scarpati G, Caponigro F, Ionna F, Longo F, Buonopane S, et al. Management of recurrent nasopharyngeal carcinoma: current perspectives. oncotargets Ther. 2019;12:1583\u201391.","journal-title":"oncotargets Ther"},{"issue":"1","key":"7418_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41698-024-00601-1","volume":"8","author":"X Liu","year":"2024","unstructured":"Liu X, Shen H, Zhang L, Huang W, Zhang S, Zhang B. Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma. NPJ Precis Oncol. 2024;8(1):101.","journal-title":"NPJ Precis Oncol"},{"key":"7418_CR5","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1002\/ijc.32869","volume":"146","author":"L Masterson","year":"2020","unstructured":"Masterson L, Howard J, Gonzalez-Cruz J, Jackson C, Barnett C, Overton L, et al. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: beyond an era of chemoradiation? Int. J. Cancer. 2020;146:2305\u201314.","journal-title":"Int. J. Cancer"},{"key":"7418_CR6","doi-asserted-by":"publisher","first-page":"175883592210962","DOI":"10.1177\/17588359221096214","volume":"14","author":"J-Y Xu","year":"2022","unstructured":"Xu J-Y, Wei X-L, Wang Y-Q, Wang F-H. Current status and advances of immunotherapy in nasopharyngeal carcinoma. Ther Adv Med Oncol. 2022;14:17588359221096214.","journal-title":"Ther Adv Med Oncol"},{"key":"7418_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1245\/s10434-016-5376-z","volume":"23","author":"S Ito","year":"2016","unstructured":"Ito S, Okano S, Morita M, Saeki H, Tsutsumi S, Tsukihara H, et al. Expression of PD-L1 and hla class I in esophageal squamous cell carcinoma: prognostic factors for patient outcome. Ann Surg Oncol. 2016;23:508\u201315.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"7418_CR8","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","volume":"11","author":"JH Lee","year":"2020","unstructured":"Lee JH, Shklovskaya E, Lim SY, Carlino MS, Menzies AM, Stewart A, et al. Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition. Nat Commun. 2020;11(1):1897.","journal-title":"Nat Commun"},{"key":"7418_CR9","doi-asserted-by":"publisher","first-page":"8131","DOI":"10.1007\/s00432-023-04737-8","volume":"149","author":"A Kallingal","year":"2023","unstructured":"Kallingal A, Olszewski M, Maciejewska N, Brankiewicz W, Baginski M. Cancer immune escape: the role of antigen presentation machinery. J Cancer Res Clin Oncol. 2023;149:8131\u201341.","journal-title":"J Cancer Res Clin Oncol"},{"key":"7418_CR10","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1038\/s41467-021-24348-6","volume":"12","author":"JP Bruce","year":"2021","unstructured":"Bruce JP, To K-F, Lui VWY, Chung GTY, Chan Y-Y, Tsang CM, et al. Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-\u03baB activation and immune escape. Nat Commun. 2021;12:4193.","journal-title":"Nat Commun"},{"issue":"1","key":"7418_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3892\/mco.2013.194","volume":"2","author":"YX Ren","year":"2014","unstructured":"Ren YX, Yang J, Zhang LJ, Sun RM, Zhao LF, Zhang M, et al. Downregulation of expression of transporters associated with antigen processing 1 and 2 and human leukocyte antigen I and its effect on immunity in nasopharyngeal carcinoma patients. Mol Clin Oncol. 2014;2(1):51\u201358.","journal-title":"Mol Clin Oncol"},{"issue":"6","key":"7418_CR12","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/1097-0215(20001215)88:6<949::AID-IJC18>3.0.CO;2-6","volume":"88","author":"Y Yao","year":"2000","unstructured":"Yao Y, Minter HA, Chen X, Reynolds GM, Bromley M, Arrand JR. Heterogeneity of HLA and EBER expression in epstein-barr virus-associated nasopharyngeal carcinoma. Int. J. Cancer. 2000;88(6):949\u201355.","journal-title":"Int. J. Cancer"},{"issue":"11","key":"7418_CR13","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1002\/ijc.22334","volume":"120","author":"T Ogino","year":"2007","unstructured":"Ogino T, Moriai S, Ishida Y, Ishii H, Katayama A, Miyokawa N, et al. Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma. Int. J. Cancer. 2007;120(11):2401\u201310.","journal-title":"Int. J. Cancer"},{"key":"7418_CR14","doi-asserted-by":"publisher","first-page":"14121","DOI":"10.1038\/ncomms14121","volume":"8","author":"YY Li","year":"2017","unstructured":"Li YY, Chung GT, Lui VW, To KF, Ma BB, Chow C, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-\u03baB pathway activating mutations. Nat Commun. 2017;8:14121.","journal-title":"Nat Commun"},{"key":"7418_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00262-011-1153-9","volume":"61","author":"B Seliger","year":"2012","unstructured":"Seliger B. Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother. 2012;61:249\u201354.","journal-title":"Cancer Immunol Immunother"},{"key":"7418_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","volume":"39","author":"F Garrido","year":"2016","unstructured":"Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. 2016;39:44\u201351.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"7418_CR17","doi-asserted-by":"publisher","first-page":"e1000255","DOI":"10.1371\/journal.ppat.1000255","volume":"5","author":"J Zuo","year":"2009","unstructured":"Zuo J, Currin A, Griffin BD, Shannon-Lowe C, Thomas WA, Ressing ME, et al. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog. 2009;5(1):e1000255.","journal-title":"PLoS Pathog"},{"key":"7418_CR18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1042\/BST20210961","volume":"50","author":"A Balasubramanian","year":"2022","unstructured":"Balasubramanian A, John T, Asselin-Labat M-L. Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance. Biochem Soc Trans. 2022;50:825\u201337.","journal-title":"Biochem Soc Trans"},{"key":"7418_CR19","doi-asserted-by":"publisher","first-page":"108111","DOI":"10.1016\/j.pharmthera.2022.108111","volume":"236","author":"DR Principe","year":"2022","unstructured":"Principe DR, Kamath SD, Korc M, Munshi HG. The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. Pharmacol Ther. 2022;236:108111.","journal-title":"Pharmacol Ther"},{"issue":"20","key":"7418_CR20","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","volume":"330","author":"H-Q Mai","year":"2023","unstructured":"Mai H-Q, Chen Q-Y, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. Jama. 2023;330(20):1961\u201370.","journal-title":"Jama"},{"issue":"1","key":"7418_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-023-01899-4","volume":"22","author":"X Wu","year":"2023","unstructured":"Wu X, Li T, Jiang R, Yang X, Guo H, Yang R. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Mol Cancer. 2023;22(1):194.","journal-title":"Mol Cancer"},{"key":"7418_CR22","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","volume":"73","author":"EP Hui","year":"2013","unstructured":"Hui EP, Taylor GS, Jia H, Ma BBY, Chan SL, Ho R, et al. Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res. 2013;73:1676\u201388.","journal-title":"Cancer Res"},{"key":"7418_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nat. 2020;585:107\u201312.","journal-title":"Nat"},{"key":"7418_CR24","doi-asserted-by":"publisher","first-page":"e0130464","DOI":"10.1371\/journal.pone.0130464","volume":"10","author":"SJ Chai","year":"2015","unstructured":"Chai SJ, Yap YY, Foo YC, Yap LF, Ponniah S, Teo SH, et al. Identification of four-jointed box 1 (FJX1)-specific peptides for immunotherapy of nasopharyngeal carcinoma. PLoS One. 2015;10:e0130464.","journal-title":"PLoS One"},{"issue":"1","key":"7418_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/21645515.2018.1520584","volume":"15","author":"SJ Chai","year":"2019","unstructured":"Chai SJ, Fong SCY, Gan CP, Pua KC, Lim PVH, Lau SH, et al. In vitro evaluation of dual-antigenic PV1 peptide vaccine in head and neck cancer patients. Hum Vaccin Immunother. 2019;15(1):167\u201378.","journal-title":"Hum Vaccin Immunother"},{"key":"7418_CR26","doi-asserted-by":"publisher","first-page":"763086","DOI":"10.3389\/fimmu.2021.763086","volume":"12","author":"C Wang","year":"2021","unstructured":"Wang C, Zainal NS, Chai SJ, Dickie J, Gan CP, Zulaziz N, et al. DNA vaccines targeting novel cancer-associated antigens frequently expressed in head and neck cancer enhance the efficacy of checkpoint inhibitor. Front Immunol. 2021;12:763086.","journal-title":"Front Immunol"},{"key":"7418_CR27","doi-asserted-by":"publisher","first-page":"e000974","DOI":"10.1136\/jitc-2020-000974","volume":"8","author":"JC Thompson","year":"2020","unstructured":"Thompson JC, Davis C, Deshpande C, Hwang W-T, Jeffries S, Huang A, et al. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. J immunother Cancer. 2020;8:e000974.","journal-title":"J immunother Cancer"},{"key":"7418_CR28","doi-asserted-by":"crossref","unstructured":"Xiao Y, Hsiao T-H, Suresh U, Chen H-IH, Wu X, Wolf SE, et al. A novel significance score for gene selection and ranking. Bioinform. 2014;30(6):801\u201307.","DOI":"10.1093\/bioinformatics\/btr671"},{"key":"7418_CR29","unstructured":"Garrido F, Cabrera T, Accolla R, Bensa J, Bodmer W, Dohr G, et al. In: Charron D, editor. Genetic Diversity of HLA: Functional and Medical Implications Proceedings of the 12th International Histocompatibility Workshop and Conference1996. p. 445\u201352."},{"issue":"1","key":"7418_CR30","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1038\/s41467-018-06889-5","volume":"9","author":"W Lin","year":"2018","unstructured":"Lin W, Yip YL, Jia L, Deng W, Zheng H, Dai W, et al. Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinoma. Nat Commun. 2018;9(1):4663.","journal-title":"Nat Commun"},{"issue":"3","key":"7418_CR31","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1158\/2767-9764.CRC-23-0341","volume":"4","author":"AWY Chai","year":"2024","unstructured":"Chai AWY, Yee SM, Lee HM, Abdul Aziz N, Yee PS, Marzuki M, et al. Establishment and characterization of an Epstein-Barr virus-positive cell Line from a non-keratinizing differentiated primary nasopharyngeal carcinoma. Cancer Res Commun. 2024;4(3):645\u201359.","journal-title":"Cancer Res Commun"},{"key":"7418_CR32","doi-asserted-by":"publisher","first-page":"104357","DOI":"10.1016\/j.ebiom.2022.104357","volume":"86","author":"LKY Chow","year":"2022","unstructured":"Chow LKY, Chung DLS, Tao L, Chan KF, Tung SY, Ngan RKC, et al. Epigenomic landscape study reveals molecular subtypes and EBV-associated regulatory epigenome reprogramming in nasopharyngeal carcinoma. EBioMedicine. 2022;86:104357.","journal-title":"EBioMedicine"},{"key":"7418_CR33","doi-asserted-by":"publisher","first-page":"e1151593","DOI":"10.1080\/2162402X.2016.1151593","volume":"5","author":"GM Rodriguez","year":"2016","unstructured":"Rodriguez GM, Bobbala D, Serrano D, Mayhue M, Champagne A, Saucier C, et al. NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8+ T lymphocytes. Oncoimmunology. 2016;5:e1151593.","journal-title":"Oncoimmunology"},{"issue":"4","key":"7418_CR34","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","volume":"178","author":"JL Benci","year":"2019","unstructured":"Benci JL, Johnson LR, Choa R, Xu Y, Qiu J, Zhou Z, et al. Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade. Cell. 2019;178(4):933\u201348.e14.","journal-title":"Cell"},{"issue":"10","key":"7418_CR35","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.4049\/jimmunol.161.10.5516","volume":"161","author":"J Wang","year":"1998","unstructured":"Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. The J Immunol. 1998;161(10):5516\u201324.","journal-title":"The J Immunol"},{"issue":"31","key":"7418_CR36","doi-asserted-by":"publisher","first-page":"13794","DOI":"10.1073\/pnas.1008684107","volume":"107","author":"TB Meissner","year":"2010","unstructured":"Meissner TB, Li A, Biswas A, Lee K-H, Liu Y-J, Bayir E, et al. NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc Natl Acad Sci U S A. 2010;107(31):13794\u201399.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7418_CR37","doi-asserted-by":"crossref","unstructured":"Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B, et al, editors. NLRC5\/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci U S A. 2016.","DOI":"10.1073\/pnas.1602069113"},{"key":"7418_CR38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.trecan.2016.12.003","volume":"3","author":"S Yoshihama","year":"2017","unstructured":"Yoshihama S, Vijayan S, Sidiq T, Kobayashi KS. NLRC5\/CITA: a key player in cancer immune surveillance. Trends Cancer. 2017;3:28\u201338.","journal-title":"Trends Cancer"},{"key":"7418_CR39","doi-asserted-by":"publisher","first-page":"3857853","DOI":"10.1155\/2019\/3857853","volume":"2019","author":"SJ Chai","year":"2019","unstructured":"Chai SJ, Ahmad Zabidi MM, Gan SP, Rajadurai P, Lim PVH, Ng CC, et al. An oncogenic role for four-jointed box 1 (FJX1) in nasopharyngeal carcinoma. Dis Markers. 2019;2019:3857853.","journal-title":"Dis Markers"},{"issue":"1","key":"7418_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.canlet.2012.03.025","volume":"321","author":"CE Chong","year":"2012","unstructured":"Chong CE, Lim KP, Gan CP, Marsh CA, Zain RB, Abraham MT, et al. Over-expression of MAGED4B increases cell migration and growth in oral squamous cell carcinoma and is associated with poor disease outcome. Cancer Lett. 2012;321(1):18\u201326.","journal-title":"Cancer Lett"},{"issue":"1","key":"7418_CR41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.pharmthera.2012.03.006","volume":"135","author":"PM George","year":"2012","unstructured":"George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012;135(1):44\u201353.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"7418_CR42","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/CMR.0b013e328364c0ed","volume":"23","author":"DM Woods","year":"2013","unstructured":"Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, et al. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res. 2013;23(5):341\u201348.","journal-title":"Melanoma Res"},{"issue":"23","key":"7418_CR43","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.7150\/jca.34471","volume":"10","author":"T Sun","year":"2019","unstructured":"Sun T, Li Y, Yang W, Wu H, Li X, Huang Y, et al. Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells. J Cancer. 2019;10(23):5638\u201345.","journal-title":"J Cancer"},{"issue":"12","key":"7418_CR44","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1002\/1878-0261.12953","volume":"15","author":"W Blaszczak","year":"2021","unstructured":"Blaszczak W, Liu G, Zhu H, Barczak W, Shrestha A, Albayrak G, et al. Immune modulation underpins the anti-cancer activity of HDAC inhibitors. Mol Oncol. 2021;15(12):3280\u201398.","journal-title":"Mol Oncol"},{"issue":"12","key":"7418_CR45","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nri3339","volume":"12","author":"KS Kobayashi","year":"2012","unstructured":"Kobayashi KS, van den Elsen PJ. NLRC5: a key regulator of MHC class I-dependent immune responses. Nat Rev Immunol. 2012;12(12):813\u201320.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"7418_CR46","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.4049\/jimmunol.1102671","volume":"188","author":"F Staehli","year":"2012","unstructured":"Staehli F, Ludigs K, Heinz LX, Segu\u00edn-Est\u00e9vez Q, Ferrero I, Braun M, et al. NLRC5 deficiency selectively impairs MHC class I- dependent lymphocyte killing by cytotoxic T cells. The J Immunol. 2012;188(8):3820\u201328.","journal-title":"The J Immunol"},{"issue":"13","key":"7418_CR47","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.3390\/ijms22136741","volume":"22","author":"E Shklovskaya","year":"2021","unstructured":"Shklovskaya E, Rizos H. MHC class I deficiency in solid tumors and therapeutic strategies to overcome it. Int J Mol Sci. 2021;22(13):6741.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"7418_CR48","doi-asserted-by":"publisher","first-page":"107205","DOI":"10.1016\/j.jbc.2024.107205","volume":"300","author":"B Zhu","year":"2024","unstructured":"Zhu B, Ouda R, An N, Tanaka T, Kobayashi KS. The balance between nuclear import and export of NLRC5 regulates MHC class I transactivation. J Biol Chem. 2024;300(5):107205.","journal-title":"J Biol Chem"},{"issue":"4","key":"7418_CR49","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261\u201379.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"7418_CR50","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373\u201384.","journal-title":"Nat Immunol"},{"issue":"1","key":"7418_CR51","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36\u201349.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"7418_CR52","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/2159-8290.CD-20-0812","volume":"11","author":"SS Gu","year":"2021","unstructured":"Gu SS, Zhang W, Wang X, Jiang P, Traugh N, Li Z, et al. Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade. Cancer Discov. 2021;11(6):1524\u201341.","journal-title":"Cancer Discov"},{"key":"7418_CR53","doi-asserted-by":"publisher","first-page":"e1315","DOI":"10.1002\/ctm2.1315","volume":"13","author":"Q Lin","year":"2023","unstructured":"Lin Q, Zhou Y, Ma J, Han S, Huang Y, Wu F, et al. Single-cell analysis reveals the multiple patterns of immune escape in the nasopharyngeal carcinoma microenvironment. Clin Transl Med. 2023;13:e1315.","journal-title":"Clin Transl Med"},{"issue":"1","key":"7418_CR54","doi-asserted-by":"publisher","first-page":"e005592","DOI":"10.1136\/jitc-2022-005592","volume":"11","author":"B Zhang","year":"2023","unstructured":"Zhang B, Li J, Hua Q, Wang H, Xu G, Chen J, et al. Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation. J immunother Cancer. 2023;11(1):e005592.","journal-title":"J immunother Cancer"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07418-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07418-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07418-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:03:24Z","timestamp":1766505804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07418-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7418"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07418-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7037136\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was approved by the Medical Ethics Committee of Penang General Hospital (NMRR-09\u2013944-4848) and Faculty of Dentistry, University of Malaya [DF OS 2101\/0002\/2179(L). Informed consent was obtained from all donors. The animal study was approved by Experimental Animal Ethics Committee, National University Malaysia (CRM\/2020\/KUE PENG\/25-MAR.\/1093-APR.-2020-APR.-2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the contents of the manuscript and agreed with the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KPL and NS received funding from Touchlight Genetics Ltd for works in the development of cancer vaccine. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1414"}}